In the debut episode of Missed & Dismissed, Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, talks with Charis Chambers, MD, about PCOS, the push to rename it PMOS, and why diagnostic delays so often begin in adolescence.
|Videos|July 25, 2022
A portable ultrasound device?
Author(s)Morgan Ebert
John Martin, MD, chief medical officer at Butterfly Network, discusses a recent study published in NEJM Evidence, which investigated Butterfly iQ vs a commercial ultrasound machine to detect gestational age.
Advertisement
Advertisement
Related to this article
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.
Fezolinetant (Veozah) was linked to objective and patient-reported sleep gains in OPTION-VMS, with no new safety signals observed.
HPV vaccination before pregnancy was linked to lower odds of preterm birth in a Swedish study of 624,713 births.
The prospective SOARA study will measure how often a 98%-specific ovarian cancer screening blood test leads to invasive procedures.
A new 3-part Lancet series reframes pregnancy as a cardiovascular risk window.
Wen Shen, MD, explains how clinicians can counter menopause misinformation from social media and steer patients toward evidence-based resources.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA approves pritelivir tablets to treat lesions from HSV
2
Well-woman visit upgrade, post-miscarriage ultrasound findings, cardio-obstetrics framework
3
Real-world data link fezolinetant to fewer nighttime awakenings
4
Evident ovarian cancer screening test: What SOARA will measure
5